17 Sep 2014 10:39
17 September 2014
Plethora Solutions Holdings PLC
("Plethora" or the "Company")
General Meeting Update
Plethora Solutions Holdings plc (AIM: PLE) announces that the general meeting of shareholders scheduled for today was adjourned sine die, in line with the Company's intention, as stated in the replacement Notice of General Meeting (the "Replacement Notice of General Meeting") sent to Shareholders on 1 September 2014 and the announcement made by the Company on 2 September 2014.
As described in the Replacement Notice of General Meeting, a replacement general meeting (the "Replacement General Meeting") is scheduled for 10.00 am on 18 September 2014, at which the resolutions set out in the Replacement Notice of General Meeting will be put to shareholders.
An announcement regarding the results of voting at the Replacement General Meeting will be made tomorrow.
-Ends-
Enquiries: | |
Plethora Solutions Jim Mellon, Chairman Jamie Gibson, CEO Mike Collis, CFO
| Tel : +44(0) 20 3077 5400 |
Daniel Stewart (Nomad & Joint Broker) Emma Earl / Alex Brearley (Nomad) Martin Lampshire (Broker)
| Tel : +44(0) 20 7776 6550
|
Hybridan LLP (Joint Broker) Claire Louise Noyce William Lynne
|
Tel: +44(0) 20 3713 4581 Tel: +44(0) 20 3713 4582 |
About Plethora:
Plethora is headquartered in the UK and is listed on the London Stock Exchange (AIM: PLE.L). Further information is available at www.plethorasolutions.co.uk
Plethora is focussed on seeking to launch PSD502™ for the treatment of premature ejaculation.
About PSD502™ & Premature Ejaculation:
PSD502™ is a topical spray for the treatment of premature ejaculation containing lidocaine and prilocaine in a eutectic-like mixture. In two large, double blind, pivotal Phase III studies PSD502™ showed a highly significant and clinically meaningful effect increasing mean intravaginal ejaculatory latency time at baseline from 0.5 minutes to 3.2 minutes at week 12. 87% of the patients in the studies were considered as responders with the product being well tolerated with no significant safety issues. PSD502™ also showed positive effects across a wide range of other parameters including partner satisfaction. PSD502™ was approved by the European Commission in November 2013.
Premature ejaculation is possibly the most common form of sexual dysfunction in men. Epidemiological studies conducted in the US and in Europe indicate a prevalence of 20% to 30% in men of all ages. There is currently no globally approved and effective pharmaceutical treatment for this condition.
The premature ejaculation market offers significant potential for development and growth given the absence of any widely approved pharmaceutical therapy with good patient acceptance. As a result an effective drug therapy for premature ejaculation may have a commercial potential comparable to erectile dysfunction drugs.